Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Theraclone Sciences Inc. (Seattle, Wash.) said a single dose of TCN-032 given 24 hours after viral inoculation missed the primary endpoint of reducing
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury